Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for AC Immune (ACIU) over the last 11 years, with Sep 2025 value amounting to $214.5 million.

  • AC Immune's Liabilities and Shareholders Equity fell 23.91% to $214.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $679.3 million, marking a year-over-year decrease of 27.91%. This contributed to the annual value of $214.5 million for FY2025, which is N/A change from last year.
  • AC Immune's Liabilities and Shareholders Equity amounted to $214.5 million in FY2025, which was up 81,283.85% from $263,592 recorded in FY2024.
  • In the past 5 years, AC Immune's Liabilities and Shareholders Equity ranged from a high of $286.1 million in FY2021 and a low of $206,096 during FY2023.
  • For the 3-year period, AC Immune's Liabilities and Shareholders Equity averaged around $71.7 million, with its median value being $263,592 (2024).
  • Per our database at Business Quant, AC Immune's Liabilities and Shareholders Equity tumbled by 99.89% in 2023 and then climbed by 27.90% in 2024.
  • Over the past 5 years, AC Immune's Liabilities and Shareholders Equity (Yearly) stood at $286.1 million in 2021, then tumbled by 32.54% to $193.0 million in 2022, then plummeted by 99.89% to $206,096 in 2023, then rose by 27.90% to $263,592 in 2024, then reached $214.5 million in 2025.